<DOC>
	<DOCNO>NCT02396498</DOCNO>
	<brief_summary>The study design assess safety efficacy S-1 plus cisplatin hyperthermic intraperitoneal chemotherapy stage Ⅲ patient D2 gastrectomy</brief_summary>
	<brief_title>SP Intravenous Chemotherapy Versus SP HIPEC Stage Ⅲ Patients After D2 Gastrectomy</brief_title>
	<detailed_description>The study randomize clinical trial，and subject wuill assign two arm : SP Intravenous Chemotherapy SP HIPEC .After 8 cycle treatment , assess safety efficacy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>18 ≤ age ≤ 70 year old Histologically diagnose stageⅢ gastric adenocarcinoma，and perform D2 radical gastrectomy，as well receive Antitumor therapy：chemotherapy , biological treatment molecular target therapy , etc . The Eastern Cooperative Oncology Group ( ECOG ) status ≤ 2 Having give write informed consent prior procedure relate study Expected survival time ≥3 month History severe hypersensitivity reaction ingredient S1 Cisplatin Hemoglobin＜90g/L Inadequate hematopoietic function define : white blood cell ( WBC ) less 3,500/mm^3 absolute neutrophil count ( ANC ) less 1,500/mm^3 platelet less 80,000/mm^3 Inadequate hepatic renal function define : serum bilirubin great 2 time upper limit normal range alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2.5 time ULN demonstrable liver metastasis great 5 time ULN presence liver metastases blood creatinine level great 1.5 time ULN , Creatinine clearance &lt; 60ml/min Receiving concomitant treatment fluoropyrimidine drug flucytosine drug Women pregnant lactate fertile woman childbearing potential unless use reliable appropriate contraceptive method throughout treatment period ( Including male ) Psychiatric disorder symptom make participation patient difficult Myocardial infarction , exist serious unstable angina , patient cardiac insufficiency 6 month Severe complication ( ) , e.g. , paresis intestine , ileus , radiographically confirm interstitial pneumonitis pulmonary fibrosis , glomerulonephritis , renal failure , poorlycontrolled diabetes Known DPD deficiency Participate clinical trial start trial Patient compliance bad researcher believe patient suitable treatment Known active hepatitis patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>